Company intelligence / Profile preview

Mochi Health

San Francisco, California, United Statesjoinmochi.com ↗

Ownership: Private
Employees: ~154
Development stage: Commercial

Overview

Mochi Health offers a commercial telehealth-based weight loss program using FDA-approved prescription medications—primarily GLP‑1 agonists such as semaglutide and tirzepatide—alongside registered dietitian support and behavioral therapies. The company customizes treatment plans based on individual eligibility and provides ongoing virtual care. No clinical trial results are published; the business operates in a direct-to-consumer model with high user retention rates.

Therapeutic areas: PsychiatryEndocrinology
Modalities: Small moleculeDeviceNon-pharmacological therapy
Industry: Non-Academic Healthcare

Drug pipeline

1 asset

semaglutide

Commercial

Indications: Obesity

Partnerships

Compounding pharmacies for medication supply

Beyond the preview

Go deeper on Mochi Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mochi Health.

Explore the full profile